Physician profile
Sam Bebawy
NPI 1396717971
$19,262.00
in general payments reported to CMS, 2019-2025
47 companies · $2,563 in 2025
The $2,563 reported for 2025 was more than what 80% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,195 · 2020: $1,111 · 2021: $2,516 · 2022: $3,480 · 2023: $4,445 · 2024: $2,951 · 2025: $2,563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,959.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,959.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,455.12 | 2019-2025 | Tezspire, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $3,313.98 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Actelion Pharmaceuticals US, INC. | $1,556.72 | 2019-2025 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,170.01 | 2019-2025 | Ofev, Jascayd, Jardiance |
| Mallinckrodt Hospital Products INC. | $906.10 | 2020-2025 | Acthar |
| United Therapeutics Corporation | $617.69 | 2019-2025 | Orenitram, Tyvaso, Tyvaso |
| Insmed, INC. | $606.49 | 2019-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $591.60 | 2019-2025 | |
| Ani Pharmaceuticals, INC. | $580.95 | 2022-2025 | Purified Cortrophin Gel |
| Electromed, INC. | $497.34 | 2019-2024 | Smartvest |
| Harmony Biosciences LLC | $487.87 | 2020-2024 | Wakix |
| Verona Pharma, INC. | $435.87 | 2025 | Ohtuvayre |
| Bayer Healthcare Pharmaceuticals INC. | $387.53 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $379.72 | 2020-2023 | Aralast, Cuvitru |
| Mylan Specialty L.P. | $358.80 | 2019-2024 | Yupelri |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Bebawy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.